Clinical trials: Prostate Cancer (Post Prostatectomy)
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery.
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT02830165
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Urinary Incontinence, Prostate Cancer
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Many men develop urine leakage after prostate cancer surgery. Usually it is temporary, but pelvic floor muscle training and exercise (including urine control strategies) have been shown to reduce the time to regaining urine…
- Trial name
- ProsTel (NCT01960998)
- Testing
- Pelvic Floor Muscle Training, Perioperative Care and Wetness Management
- Where
- 3 sites in United States
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Prostate Cancer, Venous Thromboembolism
PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous…
- Conditions
- Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis
- Trial name
- PREVENTER (NCT03006562)
- Testing
- Subcutaneous Heparin
- Where
- United States
- Volunteers
- 501 people
- Sponsor
- Johns Hopkins University
Prostate Cancer
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation…
- Trial name
- NCT03311555
- Testing
- Apalutamide, Androgen deprivation, Salvage radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Andrew J. Armstrong, MD
Adenocarcinoma of the Prostate
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
The primary hypothesis of this study is that outcomes for patients with biochemically recurrent prostate cancer following radical prostatectomy will be improved by the addition of enzalutamide for 6-months compared to…
- Trial name
- NCT02203695
- Testing
- Enzalutamide, SRT
- Where
- 9 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer Of Prostate, Prostate Neoplasms
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Background: Sometimes prostate cancer comes back after a person's prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective.
- Conditions
- Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate
- Trial name
- NCT03388619
- Testing
- Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months…
- Trial name
- NCT00669162
- Testing
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical…
- Trial name
- CAP (NCT00132301)
- Testing
- Docetaxel, Prednisone
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy
This study is designed to assess the effect of catheter size on postoperative catheter pain, urinary continence, urinary flow rates, post void residuals, International Prostate Symptom Scores (IPSS), and Quality of Life (QoL)…
- Trial name
- NCT04098809
- Testing
- 16 French urinary catheter, 20 French urinary catheter
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Benaroya Research Institute
Prostate Cancer
Postoperative Pain Control for Prostatectomy
The researchers propose to investigate a relatively new anesthetic procedure, in order to maximize patient comfort and minimize the use of narcotics after a radical prostatectomy.
- Trial name
- TAP (NCT00913068)
- Testing
- Transverse Abdominal Plan (TAP), standard post op pain control
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- Nova Scotia Health Authority
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- NCT03043807
- Testing
- Leuprolide Acetate, Docetaxel, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Penile Diseases
Penile Length Maintenance Post-Prostatectomy
The objective of the current study is to evaluate the efficacy of a novel, class I (ie. lowest risk, clinical studies not required) medical penile traction device in preventing loss of penile length in men undergoing…
- Trial name
- NCT03500419
- Testing
- RestoreX, No treatment
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Erectile Dysfunction, Prostate Cancer
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
The purpose of the study is to compare the safety and effectiveness of Prograf in the prevention of erectile dysfunction in men after a radical prostatectomy.
- Trial name
- NCT00106392
- Testing
- Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 131 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence, Stress
A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical outcomes data for future publication.
- Trial name
- AMS051 (NCT00904969)
- Testing
- The AMS Male Transobturator Sling System, AdVance Male Sling
- Where
- 11 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- American Medical Systems
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells.
- Trial name
- NCT03412396
- Testing
- Apalutamide, Quality-of-Life Assessment, Radical Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasms
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
The purpose of this study is to see how well PROSTVAC -V/F works in stopping prostate cancer from coming back or relapsing. This study will also look at the safety of PROSTVAC-V/F.
- Trial name
- NCT02772562
- Testing
- PROSTVAC-V/F
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Urinary Incontinence
Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Prostate cancer is the most common non-cutaneous malignancy in men and is the 2nd leading cause of death from cancer in men. Radical prostatectomy is one of the treatment options available for organ-confined disease.
- Trial name
- NCT01215721
- Testing
- Vesicare
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Irvine
Prostate Cancer
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002874
- Testing
- bicalutamide, radiation therapy
- Where
- 240 sites in United States, Canada
- Volunteers
- 840 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Prostate Adenocarcinoma
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
1. The investigators hypothesize that increasing radiation dose to the functional MRI-defined lesion in the prostate bed will result in an improved initial complete response (reduction in prostate-specific antigen (PSA) to < 0.1…
- Trial name
- MAPS (NCT01411345)
- Testing
- Standard Salvage Radiation Treatment (SSRT), Mapped Tumor Salvage RT (MTSRT)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Miami